“Concert Health and AIMS Center Join Forces to Expand Telepsychiatry Care” Concert Health, a leading Collaborative Care platform, and the AIMS Center at the University of Washington Department of Psychiatry…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a leading oncology firm, revealed today that the European Commission (EC) has granted approval for tislelizumab as a treatment for non-small cell…
KKR, a prominent global investment firm, along with Impilo, a Nordic healthcare investment firm, has agreed to acquire Immedica Pharma, a Swedish-based pharmaceutical company specializing in rare diseases and specialty…
ImmunityBio, Inc. (NASDAQ: IBRX), a leader in immunotherapy, has just received FDA approval for ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG). This approval marks a…
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical firm dedicated to pioneering treatments for neurological disorders and cardio-renal disease, has disclosed the dosing of the first patient in its relaunched…
Saghmos Therapeutics, Inc. (Saghmos), a privately owned biopharmaceutical firm, has disclosed its collaboration with the Duke Clinical Research Institute (DCRI) to enhance and strategize the implementation of Saghmos’ Phase 3…
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical company specializing in muscle diseases, has unveiled encouraging two-year topline results from the ARCH trial. The ARCH study, conducted at a single…
Fresenius Kabi, a division of Fresenius, has launched Tyenne® (tocilizumab-aazg) in the U.S., a biosimilar of Actemra® (tocilizumab), approved by the FDA on March 5, 2024. Tyenne® is available in…
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical firm focused on innovative treatments for spinal muscular atrophy and other serious conditions, announced granting inducement equity awards to two new employees. These…
The latest addition to ResearchAndMarkets.com’s offerings: Global Research Antibodies & Reagents Market Forecast 2024-2029. The Global Research Antibodies & Reagents Market witnessed a valuation of USD 13.39 billion in 2023,…
Today, TheracosBio announced the publication of a study in the Journal of Diabetes titled “Comparison of Bexagliflozin with Dapagliflozin as an Adjunct to Metformin in Chinese Patients with Type 2…
Today, Gennao Bio, a private genetic medicine enterprise pioneering targeted nucleic acid therapies, revealed fresh preclinical findings regarding the use of its non-viral, cell-penetrating gene monoclonal antibody (GMAB) platform technology.…